Current Report Filing (8-k)
January 31 2023 - 08:12AM
Edgar (US Regulatory)
0000078003false00000780032023-01-312023-01-310000078003us-gaap:CommonStockMember2023-01-312023-01-310000078003pfe:NotesDue20271.000Member2023-01-312023-01-31
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): January 31,
2023
PFIZER INC.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
|
|
|
|
|
Delaware |
1-3619 |
13-5315170 |
|
(State or other |
(Commission File |
(I.R.S. Employer |
|
jurisdiction of |
Number) |
Identification No.) |
|
incorporation) |
|
|
|
|
|
|
|
|
|
|
|
|
235 East 42nd Street |
10017 |
|
New York, |
New York |
(Zip Code) |
(Address of principal executive offices)
Registrant’s telephone number, including area code:
(212) 733-2323
(Former name or former address, if changed since last
report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the obligation of the registrant under
any of the following provisions (see General Instruction A.2.
below):
☐
Written communication pursuant to Rule 425 under the Securities Act
(17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act
(17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2 (b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Securities registered pursuant to Section 12(b) of the
Act: |
|
|
|
|
|
|
Title of each class |
|
Trading Symbol(s) |
|
Name of each exchange on which registered |
|
Common Stock, $.05 par value |
|
PFE |
|
New York Stock Exchange |
|
1.000% Notes due 2027 |
|
PFE27 |
|
New York Stock Exchange |
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933
(§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act.
☐
Item 2.02 Results of Operations and Financial
Condition
On January 31, 2023, Pfizer Inc. (“Pfizer”) issued a press
release announcing its financial results for fourth-quarter and
full-year 2022. A copy of the press release is furnished herewith
as Exhibit 99 and is incorporated by reference herein.
The information furnished pursuant to this “Item 2.02 - Results of
Operations and Financial Condition”, including Exhibit 99, shall
not be deemed to be “filed” for the purposes of Section 18 of the
Securities Exchange Act of 1934, as amended (“Exchange Act”) or
otherwise subject to the liabilities of that section, and shall not
be deemed to be incorporated by reference into any filing made by
us under the Exchange Act or Securities Act of 1933, as amended,
regardless of any general incorporation language in any such
filing, except as shall be expressly set forth by specific
reference in such filing.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits
|
|
|
|
|
|
|
|
|
|
Exhibit Number |
|
Exhibit Description |
|
|
|
|
|
|
|
Press Release of Pfizer Inc. dated January 31, 2023, reporting
Pfizer’s financial results for fourth-quarter and full-year
2022. |
|
104 |
|
Cover Page Interactive Data File--the cover page XBRL tags are
embedded within the Inline XBRL document. |
|
|
|
|
|
|
|
|
|
|
|
EXHIBIT INDEX |
|
|
|
|
Exhibit No. |
|
Description |
|
|
|
|
|
|
|
Press Release of Pfizer Inc. dated
January 31, 2023, reporting Pfizer’s financial
results for fourth-quarter and full-year 2022. |
|
104 |
|
Cover Page Interactive Data File--the cover page XBRL tags are
embedded within the Inline XBRL document. |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned hereunto duly
authorized.
|
|
|
|
|
|
|
|
|
|
|
PFIZER INC. |
|
|
|
|
|
|
|
|
|
|
By: |
/s/ Margaret M. Madden |
|
|
|
Margaret M. Madden |
|
|
|
Senior Vice President and Corporate Secretary |
|
|
|
Chief Governance Counsel |
|
|
|
|
|
|
|
|
Dated: January 31, 2023
Pfizer (NYSE:PFE)
Historical Stock Chart
From Mar 2023 to Mar 2023
Pfizer (NYSE:PFE)
Historical Stock Chart
From Mar 2022 to Mar 2023
